Quarterly report · Q2
3055.TEDINET S100PK8H
Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥129.4bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥248.4bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥122.0bn | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥1.1bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥759m | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥1.7bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥3.4bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.4bn | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥2.1bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥1.7bn | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.4bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.8bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.2bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥1.4bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥1.2bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥140.6bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥136.9bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥137.0bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥83.9bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥81.3bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥56.6bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥55.5bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥55.4bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥21.4bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥21.1bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥21.4bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥21.1bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥22.6bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥20.4bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.1bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥3.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥3.1bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥122m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥224m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥633m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥849m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥648m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥62.94 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥25.94 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥123.44 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥52.06 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥24.17 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 40.3% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.6% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.5% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 56
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2022-04-01 → 2022-09-30 | ¥1.6bn |
| Otherother segments | revenue external | 2022-04-01 → 2022-09-30 | ¥30m |
| Otherother segments | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥1.6bn |
| Otherother segments | segment profit | 2022-04-01 → 2022-09-30 | ¥910m |
| jpcrp040300-q2r_E03003-000Dispensing Industryreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥6.7bn |
| jpcrp040300-q2r_E03003-000Dispensing Industryreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥6.7bn |
| jpcrp040300-q2r_E03003-000Dispensing Industryreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥6m |
| jpcrp040300-q2r_E03003-000Dispensing Industryreportable segment | segment profit | 2022-04-01 → 2022-09-30 | −¥40m |
| jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥848m |
| jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥217m |
| jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥631m |
| jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥20m |
| jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥33.0bn |
| jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥32.7bn |
| jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥251m |
| jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥777m |
| jpcrp040300-q2r_E03003-000Nursing Industryreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥2.0bn |
| jpcrp040300-q2r_E03003-000Nursing Industryreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥2.0bn |
| jpcrp040300-q2r_E03003-000Nursing Industryreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥1m |
| jpcrp040300-q2r_E03003-000Nursing Industryreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥172m |
| jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥92.3bn |
| jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥87.7bn |
| jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥4.5bn |
| jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥347m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥136.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥129.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥7.0bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥2.2bn |
| Otherother segments | revenue | 2021-04-01 → 2021-09-30 | ¥1.0bn |
| Otherother segments | revenue external | 2021-04-01 → 2021-09-30 | ¥30m |
| Otherother segments | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥991m |
| Otherother segments | segment profit | 2021-04-01 → 2021-09-30 | ¥345m |
| jpcrp040300-q2r_E03003-000Dispensing Industryreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥6.7bn |
| jpcrp040300-q2r_E03003-000Dispensing Industryreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥6.7bn |
| jpcrp040300-q2r_E03003-000Dispensing Industryreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥7m |
| jpcrp040300-q2r_E03003-000Dispensing Industryreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥40m |
| jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥675m |
| jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥217m |
| jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥457m |
| jpcrp040300-q2r_E03003-000Information And Communication Technology Industryreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥28m |
| jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥30.7bn |
| jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥30.4bn |
| jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥237m |
| jpcrp040300-q2r_E03003-000Medical Equipment Wholesale Industryreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥572m |
| jpcrp040300-q2r_E03003-000Nursing Industryreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥1.9bn |
| jpcrp040300-q2r_E03003-000Nursing Industryreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥1.9bn |
| jpcrp040300-q2r_E03003-000Nursing Industryreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥5m |
| jpcrp040300-q2r_E03003-000Nursing Industryreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥157m |
| jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥87.2bn |
| jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥82.8bn |
| jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥4.5bn |
| jpcrp040300-q2r_E03003-000Wholesaler Of Drugs Industryreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥113m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-09-30 | ¥128.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-09-30 | ¥122.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥6.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-09-30 | ¥1.3bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 550
| Item | Context | Value | Unit |
|---|---|---|---|
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E03003-000InformationAndCommunicationTechnologyIndustryReportableSegmentsMember | 675000000 | JPY |
| Net sales | Prior1YTDDuration_OtherReportableSegmentsMember | 1022000000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 128213000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E03003-000WholesalerOfDrugsIndustryReportableSegmentsMember | 113000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E03003-000MedicalEquipmentWholesaleIndustryReportableSegmentsMember | 572000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E03003-000DispensingIndustryReportableSegmentsMember | 40000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E03003-000NursingIndustryReportableSegmentsMember | 157000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E03003-000InformationAndCommunicationTechnologyIndustryReportableSegmentsMember | 28000000 | JPY |
| Operating income | Prior1YTDDuration_OtherReportableSegmentsMember | 345000000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 1258000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E03003-000WholesalerOfDrugsIndustryReportableSegmentsMember | 87710000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E03003-000MedicalEquipmentWholesaleIndustryReportableSegmentsMember | 32713000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E03003-000DispensingIndustryReportableSegmentsMember | 6710000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E03003-000NursingIndustryReportableSegmentsMember | 1988000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E03003-000InformationAndCommunicationTechnologyIndustryReportableSegmentsMember | 217000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_OtherReportableSegmentsMember | 30000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 129371000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E03003-000WholesalerOfDrugsIndustryReportableSegmentsMember | 4549000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E03003-000MedicalEquipmentWholesaleIndustryReportableSegmentsMember | 251000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E03003-000DispensingIndustryReportableSegmentsMember | 6000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E03003-000NursingIndustryReportableSegmentsMember | 1000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E03003-000InformationAndCommunicationTechnologyIndustryReportableSegmentsMember | 631000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_OtherReportableSegmentsMember | 1572000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 7012000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E03003-000WholesalerOfDrugsIndustryReportableSegmentsMember | 92260000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E03003-000MedicalEquipmentWholesaleIndustryReportableSegmentsMember | 32964000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E03003-000DispensingIndustryReportableSegmentsMember | 6716000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E03003-000NursingIndustryReportableSegmentsMember | 1990000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E03003-000InformationAndCommunicationTechnologyIndustryReportableSegmentsMember | 848000000 | JPY |
| Net sales | CurrentYTDDuration_OtherReportableSegmentsMember | 1602000000 | JPY |
| Net sales | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 136383000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E03003-000WholesalerOfDrugsIndustryReportableSegmentsMember | 347000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E03003-000MedicalEquipmentWholesaleIndustryReportableSegmentsMember | 777000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E03003-000DispensingIndustryReportableSegmentsMember | -40000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E03003-000NursingIndustryReportableSegmentsMember | 172000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E03003-000InformationAndCommunicationTechnologyIndustryReportableSegmentsMember | 20000000 | JPY |
| Operating income | CurrentYTDDuration_OtherReportableSegmentsMember | 910000000 | JPY |
| Operating income | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 2188000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)北海道財務局長 | |
| Filing date cover page | FilingDateInstant | 2022-11-14 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第17期第２四半期（自 2022年７月１日 至 2022年９月30日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)株式会社ほくやく・竹山ホールディングス | |
| Company name in english cover page | FilingDateInstant | HOKUYAKU TAKEYAMA Holdings,Inc. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 眞鍋 雅信 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)札幌市中央区北６条西16丁目１番地５ | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | ０１１（６３３）１０３０ | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)専務執行役員オペレーション本部長 巌 友弘 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)札幌市中央区北６条西16丁目１番地５ |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |